Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lipocine (LPCN) Free Cash Flow (2016 - 2025)

Lipocine (LPCN) has disclosed Free Cash Flow for 13 consecutive years, with -$3.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Free Cash Flow fell 5.39% year-over-year to -$3.0 million, compared with a TTM value of -$5.1 million through Sep 2025, down 3.93%, and an annual FY2024 reading of -$1.3 million, up 88.96% over the prior year.
  • Free Cash Flow was -$3.0 million for Q3 2025 at Lipocine, down from -$1.9 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $9.0 million in Q4 2021 and bottomed at -$7.0 million in Q3 2021.
  • Average Free Cash Flow over 5 years is -$1.9 million, with a median of -$2.6 million recorded in 2023.
  • The sharpest move saw Free Cash Flow skyrocketed 344.15% in 2021, then plummeted 181.8% in 2025.
  • Year by year, Free Cash Flow stood at $9.0 million in 2021, then crashed by 121.52% to -$1.9 million in 2022, then fell by 4.95% to -$2.0 million in 2023, then surged by 183.28% to $1.7 million in 2024, then plummeted by 276.47% to -$3.0 million in 2025.
  • Business Quant data shows Free Cash Flow for LPCN at -$3.0 million in Q3 2025, -$1.9 million in Q2 2025, and -$2.0 million in Q1 2025.